Pamidronate treatment of polyostotic fibrous dysplasia: Failure to prevent expansion of dysplastic lesions during childhood

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 1, 2006, Pages 75-80

  Chan, Brendan ^a   Zacharin, Margaret ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Bisphosphonates; Fibrous dysplasia of bone; McCune Albright syndrome; Pamidronate

Indexed keywords

PAMIDRONIC ACID;

ADOLESCENT; ALBRIGHT SYNDROME; ARTICLE; BONE MALFORMATION; BONE PAIN; CASE REPORT; CHILD; CHILDHOOD DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FACE DEFORMITY; HUMAN; MALE; PAIN ASSESSMENT; PRECOCIOUS PUBERTY; RADIODIAGNOSIS; SPHENOID; TIBIA FRACTURE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

EID: 32944456921     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2006.19.1.75     Document Type: Article

References (27)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N EngI J Med 1991; 325: 1688-1695.
2. Liens B, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343: 953-954.
3. Chapurlat RB, Delmas PD, Liens D, Meunier PJ. Longterm effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997; 12: 1746-1752.
4. Niskikawa M, Akatsu T, Katayama Y, Yasomoto Y, Kado S, Kugal N, Yamamoto N, Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996; 18: 9-14.
5. Sahni M, Guenther H, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004-2011.
6. Shipman C, Rogers MJ, Apperly JF, Russell GG, Croucher PJ. Bisphosphonates induce apoptosis in human myeloma. cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98: 665-672.
7. Kananen K, Volin L, Laitinen k, Alfthan, H, Ruutu T, Valimaki MJ. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D and sex hormone replacement, with or without pamidronate. J Clin Endocrinol Metab 2005; 90: 3877-3885.
8. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S. Increased IL6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996; 98: 30-35.
9. Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Robey PG, Bianco P. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site specific patterns and recurrent histological hallmarks J Pathol 1999; 187: 249-258.
10. Riminucci M, Kuznetsov SA, Cherman M, Corsi A, Bianco P, Robey PG. Osteoclastoenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL6 expression. Bone 2003; 33: 434-442.
11. Lane JM, Khan SN, O'Connor WJ, Nydick M, Hommen JP, Schneider 1?, Tomin E, Brand J, Curtin J. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 2001; 382: 6-12.
12. Isaia GC, Lala R, Defilippi C, Matarazzo P, Andreo M, Roggia C, Priolo G, de Sanctis C. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int 2002; 71: 121-128.
13. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux F. Effect of pamidronate treatment in children with polyostotic dysplasia of bone. J Clin Endocrinol Metab 2003; 88: 4569-4575.
14. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 2000; 137: 403-409.
15. Carter DR, Bouxsein ML, Marcus R. New approaches to interpreting projected bone densitometry data. J Bone Miner Res 1992; 7: 137-145.
16. Zacharin M. Paediatric; management of endocrine complications in McCune-Albright syndrome. J Paediatr Endocrinol Metab 2005; 18: 33-41.
17. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Robey PG. Fibrous dysplasia of bone in the McCune Albright syndrome. Am J Pathol 1997; 151: 1587-1600.
18. Pfeilschifter J, Ziegler R. Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome. Med Klin 1998; 93: 352-359.
19. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C. Pamidronate treatment of bone fibrous dysplasia, in nine children with McCune Albright syndrome. Acta Paediatr 2000; 89: 188-193.
20. Ozaki T, Sugihara M, Makasuka Y, Kawai A, Inoue H. Polyostotic fibrous dysplasia. A long-term follow-up of 8 patients. Int Orthop 1996; 20: 227-232.
21. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous pan-ddronate: long term effectiveness and evaluation of predictors of response to treatment. Bone 2004; 35: 235-242.
22. Kos M, Luczak K, Gidzinski J, Klempous J. Treatment of monostotic fibrous dysplasia, with pamidronate. J Craniomaxillofac Surg 2004; 32: 10-15.
23. Lee JS, FitzGibbon E, Butman JA, Dufresne CR, Kushner H, Wientroub S, Robey PG, Collins MT. Normal vision despite narrowing of the optic canal in fibrous dysplasia. N EngI J Med 2002; 347: 1670-1676.
24. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet Al, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen CC. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 2005; 20: 219-226.
25. Lofsquist C, Andersson E, Gelander L, Roberg S, Blum W, Albertsson Wikland K Reference values for IGF1 throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age and puberty. J Clin Endocrinol Metab 2001; 86: 5870-5876.
26. Terpstra L, Rauch F, Plotkin H, Travers R, Glorieux FH. Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis. J Bone Miner Res 2002 17: 1949-1953.
27. Zacharin M, Kanamakala S. Pamidronate treatment of less severe types of osteogenesis imperfecta in children. J Paediatr Endocrinol Metab 2004; 17: 1511-1518.